FDA approves immunotherapy for dMMR endometrial cancer
The anti-programmed death receptor 1 (PD-1) monotherapy Jemperli (dostarlimab) received approval for treatment of mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed after treatment ...
Apr 26, 2021
0
3